Prognostic value of serum soluble FMS-like tyrosine kinase (sFlt-1) levels in pre-eclampsia and eclampsia; a prospective cohort study

References

• Say L, Chou D, Gemmill A, Tunçalp Ö, Moller AB, Daniels J, et al. Global causes of maternal death: a WHO systematic analysis. Lancet Glob Health. 2014;2:e323–e33. doi:10.1016/S2214-109X(14)70227-X.
   PubMed Web of Science ®Google Scholar
• American College of Obstetricians and Gynecologists. Hypertension in Pregnancy. Report of the american college of obstetricians and gynecologists’ task force on hypertension in pregnancy. Obstet Gynecol. 2013;122:1122–29. doi:10.1097/01.AOG.0000437382.03963.88.
   PubMed Web of Science ®Google Scholar
• Redman CW, Sargent IL. Latest advances in understanding preeclampsia. Science. 2005;308(5728):1592–94. doi:10.1126/science.1111726.
   PubMed Web of Science ®Google Scholar
• McClure JH, Cooper GM, Clutton BTH. Centre for Maternal and Child Enquiries. Saving mothers’ lives: reviewing maternal deaths to make motherhood safer: 2006-8: a review. Br J Anaesth. 2011;107:127–32. doi:10.1093/bja/aer192.
   PubMed Web of Science ®Google Scholar
• Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, et al. Soluble endoglin and other circulating anti angiogenic factors in preeclampsia. New Eng J Med. 2006;355(10):992–1005. doi:10.1056/NEJMoa055352.
   PubMed Web of Science ®Google Scholar
• Sircar M, Thadhani R, Karumanchi SA. Pathogenesis of preeclampsia. Curr Opin Nephrol Hypertens. 2015;24(2):131–38. doi:10.1097/MNH.0000000000000105.
   PubMed Web of Science ®Google Scholar
• Wu FT, Stefanini MO, Mac Gabhann F, Kontos CD, Annex BH, Popel AS. A systems biology perspective on sVEGFR1: its biological function, pathogenic role and therapeutic use. J Cell Mol Med. 2010;14(3):528–52. doi:10.1111/j.1582-4934.2009.00941.x.
   PubMed Web of Science ®Google Scholar
• Menzies J, Magee LA, Macnab YC, Ansermino JM, Li J, Douglas MJ, et al. Current CHS and NHBPEP criteria for severe preeclampsia do not uniformly predict adverse maternal or perinatal outcomes. Hypertens Pregnancy. 2007;26:447–62. doi:10.1080/10641950701521742.
   PubMed Web of Science ®Google Scholar
• Thangaratinam S, Gallos ID, Meah N, Usman S, Ismail KM, Khan KS, et al. How accurate are maternal symptoms in predictingimpending complications in woman with preeclampsia? A systematic review and metaanalysis. Acta Obstet Gynecol Scand. 2011;90(6):564–73. doi:10.1111/j.1600-0412.2011.01111.x.
   PubMed Web of Science ®Google Scholar
• Chaiworapongsa T, Romero R, Savasan ZA, Kusanovic JP, Ogge G, Soto E, et al. Maternal plasma concentrations of angiogenic/antiangiogenic factors are of prognostic value in patients presenting to the obstetrical triage area with the suspicion of preeclampsia. J Matern Fetal Neonatal Med. 2011;24:1187–207. doi:10.3109/14767058.2011.589932.
   PubMed Web of Science ®Google Scholar
• Shanghai S 2017. Shanghai Sunred Biological Technology Co., Ltd . [ Accessed]. http://www.sunredbio.com/esearchlist.asp.
   Google Scholar
• Andersen LB, Frederiksen-Moller B, Work Havelund K, Dechend R, Jorgensen JS, Jensen BL, et al. Diagnosis of preeclampsia with soluble Fms-like tyrosine kinase 1/placental growth factor ratio: an inter-assay comparison. J Am Soc Hypertens. 2015;9(2):86–96. doi:10.1016/j.jash.2014.11.008.
   PubMed Web of Science ®Google Scholar
• Karampas GA, Eleftheriades MI, Panoulis KC, Rizou MD, Haliassos AD, Metallinou DK, et al. Prediction of pre-eclampsia combining NGAL and other biochemical markers with Doppler in the first and/or second trimester of pregnancy. Pilot Study Eur J Obstet Gynecol Reprod Biol. 2016;205:153–57. doi:10.1016/j.ejogrb.2016.08.034.
   PubMed Web of Science ®Google Scholar
• Zeisler H, Llurba E, Chantraine F, Vatish M, Staff AC, Sennstrom M, et al. Predictive Value of the sFlt-1: plGFRatio in Women with Suspected Preeclampsia. N Eng J Med. 2016;374:13–22. doi:10.1056/NEJMoa1414838.
   PubMed Web of Science ®Google Scholar
• Tang P, Xu J, Xie BJ, Wang QM. Use of serum and urinary soluble sFlt-1 and PLGF in the diagnosis of preeclampsia. Hypertens Pregnancy. 2017;36:48–52. doi:10.1080/10641955.2016.1237642.
   PubMed Web of Science ®Google Scholar
• Mckeeman GC, Ardill JE, Caldwell CM, Hunter AJ, McClure N. Soluble vascular endothelial growth factor receptor-1 (sFlt-1) is increased throughout gestation in patients who have preeclampsia develop. Am J Obstet Gynecol. 2004;191(4):1240–46. doi:10.1016/j.ajog.2004.03.004.
   PubMed Web of Science ®Google Scholar
• Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, et al. Circulating angiogenic factors and the risk of preeclampsia. N Eng J Med. 2004;350:672–83. doi:10.1056/NEJMoa031884.
   PubMed Web of Science ®Google Scholar
• Vaisbuch E, Whitty JE, Hassan SS, Romero R, Kusanovic JP, Cotton DB, et al. Circulating angiogenic and antiangiogenic factors in women with eclampsia. Am J Obstet Gynecol. 2011;204:e151–e159. doi:10.1016/j.ajog.2010.08.049.
   Web of Science ®Google Scholar
• Stepan H, Hund M, Gencay M, Denk B, Dinkel C, Kaminski WE, et al. A comparison of the diagnostic utility of the sFlt-1/PlGF ratio versus PlGF alone for the detection of preeclampsia/HELLP syndrome. Hypertens Pregnancy. 2016;35:295–305. doi:10.3109/10641955.2016.1141214.
   PubMed Web of Science ®Google Scholar
• Turpin CA, Sakyi SA, Owiredu WK, Ephraim RK, Anto EO. Association between adverse pregnancy outcome and imbalance in angiogenic regulators and oxidative stress biomarkers in gestational hypertension and preeclampsia. BMC Pregnancy Childbirth. 2015;15:189. doi:10.1186/s12884-015-0624-y.
   PubMed Web of Science ®Google Scholar
• Smith GC, Crossley JA, Aitken DA, Jenkins N, Lyall F, Cameron AD, et al. Circulating angiogenic factors in early pregnancy and the risk of preeclampsia, intrauterine growth restriction, spontaneous preterm birth, and stillbirth. Obstet Gynecol. 2007;109:1316–24. doi:10.1097/01.AOG.0000265804.09161.0d.
   PubMed Web of Science ®Google Scholar
• Masoura S, Kalogiannidis I, Makedou K, Theodoridis T, Koiou K, Gerou S, et al. Biomarkers of endothelial dysfunction in preeclampsia and neonatal morbidity: a case-control study. Eur J Obstet Gynecol Reprod Biol. 2014;175:119–23. doi:10.1016/j.ejogrb.2014.01.012.
   PubMed Web of Science ®Google Scholar
• March MI, Geahchan C, Wenger J, Raghuraman N, Berg A, Haddow H, et al. Circulating angiogenic factors and the risk of adverse outcomes among Haitian women with preeclampsia. PLoS One. 2015;10:e0126815. doi:10.1371/journal.pone.0126815.
   PubMed Web of Science ®Google Scholar